To the Editor: In reference to the letter by Kennedy et al, reporting two patients who tested positive to human T-lymphotropic virus I/II (HTLV-I/HTLV-II) antibodies after administration of the intravenous immunoglobulin, Octagam (Octapharma Australia, Sydney, NSW),1 the Therapeutic Goods Administration (TGA) would submit that:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Office of Devices, Blood and Tissues, Therapeutic Goods Administration, Canberra, ACT.
Correspondence: albert.farrugia@health.gov.au
- 1. Kennedy GA, Cummings J, Durrant ST. Potential impact of AUSFTA on Australia's blood supply [letter]. Med J Aust 2007; 186: 427. <MJA full text>
- 2. Kariya N, Hayashi K, Hoshino H, et al. Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region. Arch Virol 1996; 141: 471-480.
- 3. Northern Territory Government. Centre for Disease Control. HTLV-I. www.nt.gov.au/health//cdc/fact_sheets/HTLV1.rtf (accessed May 2007).
- 4. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005; 35: 592-598.
- 5. Schosser R, Keller-Stanislawski B, Nübling CM, Löwer J. Causality assessment of suspected virus transmission by human plasma products. Transfusion 2001; 41: 1020-1029.
Online responses are no longer available. Please refer to our instructions for authors page for more information.